FENC Stock Price, Fennec Pharmaceuticals Quote, Chart

Market Summary

USD7.03-0.09

Market Closed

-1.26%

FENC Alerts

1 major insider sales recently.

FENC Stock Price

View Fullscreen

FENC RSI Chart

FENC Valuation

Market Cap

192.1M

Price/Earnings (Trailing)

-22.2

Price/Sales (Trailing)

9.04

Price/Free Cashflow

6.99

FENC Price/Sales (Trailing)

FENC Profitability

Return on Equity

-287.06%

Return on Assets

-12.5%

Free Cashflow Yield

14.31%

FENC Fundamentals

FENC Revenue

Revenue (TTM)

21.3M

Rev. Growth (Yr)

566.71%

Rev. Growth (Qtr)

58.1%

FENC Earnings

Earnings (TTM)

-8.7M

Earnings Growth (Yr)

312.11%

Earnings Growth (Qtr)

175.68%

Breaking Down FENC Revenue

Last 7 days

-27.9%

Last 30 days

-27.5%

Last 90 days

-22.0%

Trailing 12 Months

-5.3%

How does FENC drawdown profile look like?

FENC Financial Health

Current Ratio

6.93

Debt/Equity

8.29

Debt/Cashflow

1.1

FENC Investor Care

Shares Dilution (1Y)

3.42%

Diluted EPS (TTM)

0.04

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	3.2M	9.2M	15.2M	21.3M
2022	0	161.0K	59.0K	1.5M
2021	0	0	230.0K	174.0K
2020	0	0	271.0K	287.0K
2019	355.0K	392.0K	361.0K	315.0K
2018	103.0K	171.0K	256.0K	348.0K
2017	11.0K	13.0K	26.0K	47.0K
2016	0	5.0K	7.0K	8.0K
2015	5.0K	3.0K	4.0K	3.0K
2014	0	2.0K	2.0K	2.0K
2013	20.5K	0	11.3K	2.0K
2012	44.5K	46.0K	30.0K	26.5K
2011	0	0	0	43.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Fennec Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	raykov rosty	sold	-22,152	9.1123	-2,431	chief executive officer
Apr 30, 2024	raykov rosty	acquired	-	-	2,431	chief executive officer
Apr 30, 2024	andrade robert	acquired	-	-	1,042	chief financial officer
Apr 22, 2024	haigh adrian	acquired	51,335	2.31	22,223	chief operating officer
Apr 22, 2024	haigh adrian	sold	-207,029	9.316	-22,223	chief operating officer
Apr 19, 2024	haigh adrian	acquired	51,332	2.31	22,222	chief operating officer
Apr 19, 2024	haigh adrian	sold	-207,442	9.335	-22,222	chief operating officer
Apr 18, 2024	haigh adrian	sold	-213,776	9.62	-22,222	chief operating officer
Apr 18, 2024	haigh adrian	acquired	51,332	2.31	22,222	chief operating officer

Which funds bought or sold FENC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.9	-13,220	20,294	-%
May 16, 2024	JANE STREET GROUP, LLC	new	-	172,961	172,961	-%
May 15, 2024	683 Capital Management, LLC	reduced	-65.64	-1,035,840	534,961	0.04%
May 15, 2024	MORGAN STANLEY	reduced	-3.95	-41,620	823,880	-%
May 15, 2024	STATE STREET CORP	added	14.26	394,538	3,375,130	-%
May 15, 2024	DEUTSCHE BANK AG\	added	8.86	10,012	136,921	-%
May 15, 2024	BARCLAYS PLC	reduced	-48.65	-139,000	143,000	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-58.86	-266,172	183,246	-%
May 15, 2024	Point72 (DIFC) Ltd	new	-	2,849	2,849	-%
May 15, 2024	Sonic GP LLC	unchanged	-	-240,736	26,769,800	35.34%

Are Funds Buying or Selling FENC?

Are funds buying FENC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FENC

No. of Funds

FENC Alerts

1 major insider sales recently.

Unveiling Fennec Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	solas capital management, llc	5.2%	1,378,513	SC 13G
Feb 14, 2023	sonic gp llc	9.2%	2,407,357	SC 13G/A
Feb 14, 2022	sonic fund ii, l.p.	9.3%	-	SC 13G/A
Feb 11, 2022	avoro capital advisors llc	4.6%	1,200,000	SC 13G/A
Feb 16, 2021	sonic fund ii, l.p.	9.4%	-	SC 13G
Feb 12, 2021	avoro capital advisors llc	6.5%	1,670,000	SC 13G/A
Feb 12, 2021	southpoint capital advisors lp	15.8%	4,077,214	SC 13G/A
May 04, 2020	essetifin spa	16.2%	3,993,694	SC 13D/A

Recent SEC filings of Fennec Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 13, 2024	DEF 14A	DEF 14A
May 09, 2024	8-K	Current Report
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
May 01, 2024	144	Notice of Insider Sale Intent
Apr 26, 2024	4/A	Insider Trading
Apr 26, 2024	4/A	Insider Trading
Apr 22, 2024	144	Notice of Insider Sale Intent
Apr 22, 2024	4	Insider Trading

Peers (Alternatives to Fennec Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Fennec Pharmaceuticals Inc News

Latest updates

Fennec Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2021Q4	2021Q3	2020Q4	2020Q3	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Revenue	154.9%	25,377	9,954	6,296	3,987	1,677	1,493	24.00	9.00	13.00	13.00	126	22.00	69.00	70.00	110	66.00	115	101	73.00	59.00	23.00
Gross Profit	-100.0%	-	9,050	6,184	3,177	1,582	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-37.8%	11,634	18,711	7,201	-7,843	6,852	12,593	7,899	-5,009	-	-	-	-	11,448	-	-	-	-	-	-	-	-
S&GA Expenses	34.7%	5,209	3,868	3,384	2,340	2,531	-10,255	7,053	3,878	3,684	2,931	2,293	4,491	2,481	1,068	2,844	1,009	1,382	1,050	1,867	-	-
R&D Expenses	-90.6%	3.00	32.00	12.00	8.00	4.00	117	846	1,131	523	1,242	1,223	1,368	1,172	795	1,969	1,671	1,723	1,798	798	-	-
Interest Expenses	71.3%	197	115	102	-	109	153	24.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	175.7%	12,837	-16,962	917	-5,444	-6,052	-6,857	-8,089	-5,072	-4,427	-4,185	-3,238	-6,200	-3,610	-1,809	-4,730	-2,626	-2,984	-2,749	-2,587	-	-
Net Income Margin	68.6%	-0.41*	-1.30*	-1.14*	-2.87*	-8.14*	-15.41*	-360.75*	-107.95*	-99.69*	-70.25*	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	903.4%	39,047	-4,860	-2,760	-3,946	-5,577	-6,802	-5,010	-3,390	-3,245	-2,958	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	157.6%	69.00	27.00	20.00	19.00	22.00	27.00	30.00	16.00	19.00	22.00	26.00	28.00	28.00	31.00	34.00	39.00	10.00	14.00	16.00	18.00	21.00
Current Assets	153.8%	68.00	27.00	20.00	19.00	22.00	27.00	30.00	16.00	19.00	22.00	-	28.00	28.00	31.00	34.00	39.00	10.00	14.00	16.00	18.00	20.00
Cash Equivalents	285.7%	51.00	13.00	12.00	15.00	18.00	24.00	30.00	15.00	18.00	21.00	24.00	27.00	27.00	30.00	33.00	39.00	10.00	14.00	15.00	14.00	20.00
Liabilities	72.0%	66.00	38.00	30.00	29.00	29.00	30.00	28.00	7.00	7.00	7.00	7.00	6.00	4.00	2.00	2.00	2.00	2.00	2.00	-	-	-
Current Liabilities	30.2%	10.00	8.00	4.00	4.00	4.00	5.00	3.00	3.00	2.00	2.00	2.00	1.00	3.00	2.00	3.00	3.00	2.00	2.00	1.00	1.00	1.00
Long Term Debt	-	-	-	-	-	-	-	25.00	4.00	5.00	5.00	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	-	-	-	-	-	-	-	-	1.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	25.00	4.00	5.00	5.00	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	125.9%	3.00	-11.62	10.00	-	-7.34	-2.57	3.00	9.00	13.00	16.00	19.00	22.00	25.00	29.00	31.00	36.00	8.00	12.00	15.00	16.00	19.00
Retained Earnings	5.9%	-206	-219	216	-214	-209	-203	-196	-188	-183	-179	-175	-170	-166	-162	-158	-152	-147	-144	-140	-138	-133
Additional Paid-In Capital	1.9%	63.00	62.00	61.00	60.00	58.00	57.00	57.00	55.00	54.00	53.00	52.00	51.00	50.00	49.00	49.00	49.00	49.00	48.00	48.00	47.00	45.00
Shares Outstanding	0.3%	27.00	27.00	27.00	27.00	26.00	26.00	26.00	26.00	26.00	26.00	26.00	26.00	26.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	138	-	-	-	98.00	-	-	-	98.00	-	-	-	116	-	-	-	46.00	-

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	903.4%	39,047	-4,860	-2,760	-3,946	-5,577	-6,802	-5,010	-3,390	-2,856	-3,245	-2,958	-4,426	-3,593	-3,284	-5,446	-3,116	-3,749	-1,590	-2,235	-2,756	-2,479
Share Based Compensation	39.0%	1,191	857	865	2,543	1,089	827	1,853	1,008	399	919	917	1,326	587	640	1,238	522	391	461	314	1,669	221
Cashflow From Financing	-119.8%	-1,132	5,730	201	514	193	824	19,847	46.00	15.00	10.00	-	4,968	-	462	-117	31,944	-	-	-	-	-71.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

FENC Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Condensed Consolidated Statements of Operations
PEDMARK product sales, net	$ 7,419	$ 1,677
Licensing revenue	17,958
Total revenue	25,377	1,677
Operating expenses:
Cost of product sales	550	95
Research and development	3	4
Selling and marketing	5,209	2,531
General and administrative	5,872	4,317
Total operating expenses	11,634	6,947
Net income/(loss) from operations	13,743	(5,270)
Other (expense)/income
Unrealized foreign exchange (loss)/gain	(38)	9
Amortization expense	(20)	(72)
Unrealized loss on securities	(11)	(30)
Interest income	197	109
Interest expense	(1,034)	(798)
Total other expense	(906)	(782)
Net income/(loss) from operations	$ 12,837	$ (6,052)
Basic net income/(loss) per common share	$ 0.41	$ (0.23)
Diluted net income/(loss) per common share	$ 0.41	$ (0.23)
Weighted-average number of common shares outstanding basic	27,045	26,559
Weighted-average number of common shares outstanding diluted	31,091	26,559

FENC Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 51,184	$ 13,269
Accounts receivable, net	10,274	8,814
Prepaid expenses	4,488	2,575
Inventory	2,064	2,156
Other current assets	161	44
Total current assets	68,171	26,858
Non-current assets
Other non-current assets, net of amortization	1,022	6
Total non-current assets	1,022	6
Total assets	69,193	26,864
Current liabilities:
Accounts payable	5,204	3,778
Accrued liabilities	4,363	3,754
Operating lease liability - current	17	21
Contract liability - current	252
Total current liabilities	9,836	7,553
Long term liabilities
Term loan	30,000	30,000
PIK interest	1,617	1,219
Debt discount	(268)	(288)
Contract liability - long-term	24,994	2
Total long term liabilities	56,343	30,933
Total liabilities	66,179	38,486
Commitments and Contingencies (Note 6)
Stockholders' deficit:
Common stock, no par value; unlimited shares authorized; 27,105 shares issued and outstanding (2023 27,027)	144,934	144,307
Additional paid-in capital	63,245	62,073
Accumulated deficit	(206,408)	(219,245)
Accumulated other comprehensive income	1,243	1,243
Total stockholders' deficit	3,014	(11,622)
Total liabilities and stockholders' deficit	$ 69,193	$ 26,864

About Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

CEO	Mr. Rostislav Raykov
WEBSITE	fennecpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	36

Fennec Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Fennec Pharmaceuticals Inc? What does FENC stand for in stocks?

FENC is the stock ticker symbol of Fennec Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Fennec Pharmaceuticals Inc (FENC)?

As of Fri May 17 2024, market cap of Fennec Pharmaceuticals Inc is 192.07 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FENC stock?

You can check FENC's fair value in chart for subscribers.

What is the fair value of FENC stock?

You can check FENC's fair value in chart for subscribers. The fair value of Fennec Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Fennec Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FENC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Fennec Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether FENC is over valued or under valued. Whether Fennec Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Fennec Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FENC.

What is Fennec Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, FENC's PE ratio (Price to Earnings) is -22.2 and Price to Sales (PS) ratio is 9.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FENC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Fennec Pharmaceuticals Inc's stock?

In the past 10 years, Fennec Pharmaceuticals Inc has provided 0.325 (multiply by 100 for percentage) rate of return.